Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from NeoGenomics ( (NEO) ).
On January 14, 2025, NeoGenomics announced it had awarded retention bonuses to key executives to reward and incentivize their performance. The bonuses, aimed at retaining Jeffrey Sherman, Melody Harris, and Warren Stone, include cash payments and restricted stock units, with vesting conditions linked to continued employment. The following day, NeoGenomics also provided its 2025 financial guidance, projecting revenue growth of 12-13% annually and expecting total revenues between $735 million to $745 million. The company plans to expand its leadership in oncology testing, enhance operational efficiencies, and achieve positive cash flow, reflecting its patient-centric strategy and focus on product innovation.
More about NeoGenomics
NeoGenomics, Inc. is a leading cancer diagnostics company that specializes in cancer genetics testing and information services. It offers a comprehensive range of oncology-focused testing services, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. The company operates CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom, providing full-service sample processing and analysis.
YTD Price Performance: -16.43%
Average Trading Volume: 812,235
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.77B
For detailed information about NEO stock, go to TipRanks’ Stock Analysis page.
